REGENXBIO Inc. RGNX
Set alert
7.20 USD -0.21 -2.83%
At close · Oct 30
7.20 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
7.00 Day range 7.54
5.65 52-week range 15.98
- YTD
- -50.00%
- 1 year
- -43.84%
- Open
- 7.38
- Prev close
- 7.41
- Mkt cap
- 475.29M
- Vol
- 1.06M
- Avg vol
- 1.36M
- EPS
- -3.78
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.00
- High
- 7.54
- Forward P/E
- -6.83
- Beta
- 1.23
- Short ratio
- 6.02
- Inst. own
- 92.34%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 9.58
- 200-d avg
- 13.24
- 1y target
- 37.64
2Y chart
Events in this range
- Nov 6, 2024Earnings: -1.17; estimate -1.16; surprise -0.86%
- Nov 7, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 20, 2024Rating: Chardan Capital · Buy → Buy
- Nov 21, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 11, 2024Rating: RBC Capital · Outperform → Outperform
Signals (84)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 26, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| MACD: Sell Signal | May 14, 2026 | 5 months ago |
| RSI: Oversold | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 30, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 25, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 24, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 25, 2026 | 8 months ago |
| RSI: Oversold | Feb 20, 2026 | 8 months ago |
| RSI: Oversold | Feb 10, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| SMA: Bearish | Jan 27, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 23, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 15, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 19, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 31, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 22, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 21, 2025 | 1 year ago |
| SMA: Bearish | Aug 19, 2025 | 1 year ago |
| SMA: Bullish | Aug 13, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| SMA: Bearish | Jul 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| SMA: Bearish | Jun 20, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 11, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 5, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| MACD: Sell Signal | May 28, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 9, 2025 | 1 year ago |
| SMA: Bearish | May 7, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| RSI: Overbought | May 1, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 18, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 12, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
Key statistics
- Market cap
- 365.64M
- Enterprise value
- 267.88M
- Trailing P/E
- 0.00
- Forward P/E
- -6.83
- PEG ratio
- 0.00
- Price / sales
- 4.34
- Price / book
- 1.21
- EPS (TTM)
- -5.01
- Beta
- 1.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -283.19%
- Revenue (TTM)
- 84.33M
- Revenue growth
- -16.30%
- Free cash flow
- -95.26M
- Total cash
- 255.46M
- Total debt
- 145.81M
- Return on equity
- -71.87%
- Shares outstanding
- 49.55M
- Short % of float
- 13.88%
- 50-day average
- 9.58
- 200-day average
- 13.24
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 37.64 +422.7% upside
Now 7.20
- Target (low)
- 22.00
- Target (mean)
- 37.64
- Target (high)
- 52.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy5
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.11.
Financials — quick view
RGNX Revenue — quarterly 108.02M
RGNX Net income — quarterly 22.71M
RGNX EPS — quarterly 0.43
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.16 | -1.17 | -0.01 | -0.86% |
| Aug 1, 2024 | Jun 1, 2024 | -1.29 | -1.05 | +0.24 | +18.60% |
| May 8, 2024 | Mar 1, 2024 | -1.28 | -1.38 | -0.10 | -7.81% |
| Feb 27, 2024 | Dec 1, 2023 | -1.27 | -1.43 | -0.16 | -12.60% |
| Nov 8, 2023 | Sep 1, 2023 | -1.44 | -1.41 | +0.03 | +2.08% |
| Aug 2, 2023 | Jun 1, 2023 | -1.26 | -1.66 | -0.40 | -31.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | RBC Capital | reit | Outperform | Outperform |
| Nov 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 7, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 22, 2024 | Chardan Capital | main | Buy | Buy |
| Sep 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regenxbio.com
News
- Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
- REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
- Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR)
- REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
- REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript
- REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
- Full Transcript: Regenxbio Q2 2026 Earnings Call
- Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22
- Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events
- REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
Your note
Sign in to keep a note on RGNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAN MITCHELL | Chief Financial Officer | Stock Award(Grant) | Sep 15, 2024 | 58,869 |
| CHRISTMAS PATRICK J. II | Officer | Stock Award(Grant) | Jul 31, 2024 | 172,205 |
| DANOS OLIVIER | Officer | Stock Award(Grant) | Jul 31, 2024 | 185,083 |
| KARABELAS ARGERIS N | Director | Conversion of Exercise of derivative security | Sep 30, 2024 | 11,286 |
| MIGAUSKY GEORGE V | Director | Stock Award(Grant) | May 30, 2024 | 11,286 |
| MILLS KENNETH THOMAS | Director | Conversion of Exercise of derivative security | Aug 7, 2024 | 444,351 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.85% | 8,844,466 | 65.27M | Sep 29, 2024 |
| Redmile Group, LLC | 9.88% | 4,892,902 | 36.11M | Sep 29, 2024 |
| Vanguard Group Inc | 8.82% | 4,368,991 | 32.24M | Sep 29, 2024 |
| State Street Corporation | 5.62% | 2,782,883 | 20.54M | Sep 29, 2024 |
| JP Morgan Chase & Company | 5.00% | 2,477,311 | 18.28M | Sep 29, 2024 |
| Morgan Stanley | 2.72% | 1,349,876 | 9.96M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 5.86% | 2,902,939 | 21.42M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.83% | 1,400,445 | 10.34M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.39% | 1,183,646 | 8.74M | Oct 30, 2024 |
| JP Morgan Small Cap Growth Fund | 2.35% | 1,162,623 | 8.58M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.78% | 880,902 | 6.50M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.48% | 735,639 | 5.43M | Sep 29, 2024 |